Boehringer gains global rights to Zealand's diabetes/obesity compounds in 376 million-euro deal

17 June 2011

German independent drug major Boehringer Ingelheim has signed an exclusive global licence and collaboration agreement with Denmark’s Zealand Pharma (Nasdaq OMX: ZEAL) for the latter’s dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with type-2 diabetes and patients with obesity which could cost it as much as 376 million euros ($539.9 million). Shares in the Danish firm leapt an initial 13% but settled 8.4% higher at 8.4 Danish kroner on the news.

As part of the deal, Boehringer Ingelheim obtains global development and commercialization rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will be responsible for conducting the first Phase I study with ZP2929 and the German firm will fund the research, development and commercialization of products under the agreement.

$4.5 billion sales for ZP2929 projected

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK